Your SlideShare is downloading. ×
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Myeloma Treatment Approach
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Myeloma Treatment Approach

459

Published on

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
459
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Slide shows the tremendous progress made since the early 1960's in the treatment of childhood acute leukemia at St. Jude with their 'total therapy' trials, raising cure rates from <10% to >95% in contemporary trials. The underlying philosophy was to apply all active drugs at any one time up-front rather than reserving agents for the time of relapse.
  • 2. The first ever myeloma tandem transplant trial – Total Therapy 1 – enrolled 231 patients. Shown are the long-term outcome results. At 10 years, 33% are alive and 15% have never relapsed (left panel). Duration of complete remission is depicted on the right, revealing 15 patients who are in continuous complete remission of the 94 who entered such state originally. These patients can be considered cured as all are beyond 10 years.
  • 3. This slide shows the treatment diagrams for Total Therapy 1 (TT1, top) and Total Therapy 2 (TT2, bottom). The difference in TT2 v TT1 included: a) more intensive induction therapy; b) the introduction of consolidation chemotherapy after tandem transplants with Melphalan; and, c) the addition of Dexamethasone pulsing during the first year of maintenance. All patients were randomized to receive or not to receive Thalidomide, which we discovered here to have profound anti-myeloma activity in endstage disease.

×